Renascience Inc.
【Renasa Science】 Progress in Obesity and Lifestyle Disease-Related Research｜July 2026
Renasa Science discloses research results related to obesity to investors, explaining the roles of plasma PAI-1 and the obesity-suppressing effects of P1 inhibitors.
Key Figures
- Correlation between plasma PAI-1 levels and obesity/fatty liver: Unknown
- Significant suppression of weight loss induced by RS5441 administration: Data not specified
- Suppression of weight gain in mice fed a high-fat diet: Unknown
AI要約
Research Content and Progress
Renasa Science reports that plasma PAI-1 is an important biomarker for obesity and lifestyle-related diseases, presenting research results using mouse models of P1 inhibitors RS5614 and RS5441, which are expected to have anti-obesity effects. The research confirmed suppressive effects on obesity and non-alcoholic fatty liver induced by high-fat diets, suggesting potential applicability to humans.
Future Outlook and Corporate Strategy
Focusing on the impact of anti-obesity measures on anti-aging and longevity, the company is examining the contribution of anti-obesity drugs to anti-aging and longevity effects. The research findings may support future business development and product creation, with ongoing efforts to advance research and clinical applications.
Renasa Science Inc.
Company overview · Stock price · Financial data · All IR
